PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208
Open Access
- 25 April 2020
- Vol. 9 (5), 1071
- https://doi.org/10.3390/cells9051071
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. The standard treatment in locally advanced rectal cancer is preoperative radiation alone or in combination with chemotherapy, followed by adjuvant chemotherapy. Rectal cancer is highly lethal, with only 20% of patients showing a complete remission (by RECIST) after standard treatment, although they commonly show local or systemic relapse likely due to its late detection and high chemotherapy resistance, among other reasons. Here, we explored the role of PAI1 (Serpin E1) in rectal cancer through the analyses of public patient databases, our own cohort of locally advanced rectal cancer patients and a panel of CRC cell lines. We showed that PAI1 expression is upregulated in rectal tumors, which is associated with decreased overall survival and increased metastasis and invasion in advanced rectal tumors. Accordingly, PAI1 expression is correlated with the expression of (Epithelial-to-Mesenchymal Transition) EMT-associated genes and genes encoding drug targets, including the tyrosine kinases PDGFRb, PDGFRa and FYN, the serine/threonine kinase PIM1 and BRAF. In addition, we demonstrate that cells expressing PAI1 protein are more sensitive to the PIM inhibitor AZD1208, suggesting that PAI1 could be used to predict response to treatment with PIM inhibitors and to complement radiotherapy in rectal tumors.Funding Information
- Instituto de Salud Carlos III (Sara Borrell CD16/00230)
This publication has 76 references indexed in Scilit:
- Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent NeoplasiaPLOS ONE, 2013
- MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient SurvivalPLOS ONE, 2013
- Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II ConsortiumInvestigational New Drugs, 2011
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximabOncogene, 2010
- REVIEW: Plasminogen Activator Inhibitor‐1 (PAI‐1): A Key Factor Linking Fibrinolysis and Age‐Related Subclinical and Clinical ConditionsCardiovascular Therapeutics, 2010
- Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative StressCancer Research, 2009
- PrognoScan: a new database for meta-analysis of the prognostic value of genesBMC Medical Genomics, 2009
- Transcriptome Profile of Human Colorectal AdenomasMolecular Cancer Research, 2007
- MAP17 overexpression is a common characteristic of carcinomasCarcinogenesis: Integrative Cancer Research, 2007
- Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203Journal of Clinical Oncology, 2006